Experienced in Venous Thromboembolism (VTE)

Philip P. Connor

Hamburg, HH, DE 
Experienced in Venous Thromboembolism (VTE)
Hamburg, HH, DE 
OverviewLocationsClinical Research

Overview

Philip Connor practices in Hamburg, Germany. Mr. Connor is rated as an Experienced expert by MediFind in the treatment of Venous Thromboembolism (VTE). His top areas of expertise are Thrombocytopenia, Sideroblastic Anemia, Immune Thrombocytopenic Purpura (ITP), and Dubin-Johnson Syndrome.

His clinical research consists of co-authoring 139 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Venous Thromboembolism (VTE).

Gender
Male

Locations

Hamburg, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Phase 2b Placebo-Controlled Randomized Study of BPZE1 Intranasal Pertussis Vaccine in Healthy School-Age Children to Assess Immunological Response and Safety of a Single Dose BPZE1 With/Without Coadministration of Tdap (Boostrix™)
Enrollment Status: Completed
Publish Date: January 10, 2025
Intervention Type: Biological
Study Phase: Phase 2
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination With Dexamethasone for the Treatment of Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia
Enrollment Status: Terminated
Publish Date: May 11, 2023
Intervention Type: Drug
Study Drugs: Selumetinib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

139 Total Publications

Measurement of WWZ and ZH Production Cross Sections at sqrt[s]=13 and 13.6 TeV.
Measurement of WWZ and ZH Production Cross Sections at sqrt[s]=13 and 13.6 TeV.
Journal: Physical review letters
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Connor's expertise for a condition
ConditionClose
        View All 15 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile